Post

New research · Hematology
JTO clinical and research reports · 4d
Cohort studyJTO clinical and research reports · 2026

Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion-Positive NSCLC Real-World Cohort: A Brief Report.

Alvaro Guimaraes Paula, Ximeng Liu, Amirali Karimi … John V Heymach
Read paper
HematologyCohort study

Chemotherapy plus RET inhibitor was associated with a lower hazard of progression or death.

Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion-Positive NSCLC Real-World Cohort: A Brief Report.

Alvaro Guimaraes Paula … John V Heymach
JTO clinical and research reports · 2026
Background

RET fusion-driven NSCLC accounts for 2% of advanced lung adenocarcinomas, and selective RET tyrosine kinase inhibitors (RETis) are the current first-line standard-of-care treatment.

Methods

This real-world retrospective cohort evaluated the outcomes of the combinations of chemotherapy with RETi (chemo/RETi) and chemotherapy with immunotherapy (chemo/IO) in patients with NSCLC who experienced progression while receiving RETi.

n = 12 patients
Results

chemo/RETi had a lower risk of cancer worsening or death

HR 0.24 (95% CI 0.07 to 0.83)
null 1
0.07
0.83
CI excludes the null - significant
More results

The overall response rate was 38% in the chemo/RETi group and 25% in the chemo/IO group; one metabolic complete response was observed in the chemo/RETi group.

Overall survival did not differ significantly between groups.

More results

Although chemo/RETi demonstrated improved outcomes, it was associated with more grade 3 treatment-related adverse events, including anemia, febrile neutropenia, and thrombocytopenia, compared with chemo/IO.

“
Conclusion

Our data support the potential efficacy of chemo/RETi after progression on RETi, with significantly better PFS than chemo/IO, albeit with higher rates of hematologic toxicities.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
81 cardiac deaths
potential reduction in heart-related deaths for patients switching to zanubrutinib
Cohort Study
79.2%
79.2% of patients on second-line nilotinib achieved major molecular response.
Cohort Study
AUC = 0.86
An AUC of 0.86 indicates good predictive performance for acute respiratory distress syndrome.
Guideline
“As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of AML in older patients.”
Cohort Study
3.8-fold
Sickle cell disease recipients had 3.8-fold higher odds of DNA Damage Response-mutant clonal hematopoiesis.
Randomized Trial
78%
78% of patients on irinotecan had more severe side effects
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.